

**North Georgia Bancshares, Inc.;
Formation of, Acquisition by, or
Merger of Bank Holding Companies;
and Acquisition of Nonbanking
Company**

The company listed in this notice has applied under § 225.14 of the Board's Regulation Y (12 CFR 225.14) for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) to become a bank holding company or to acquire voting securities of a bank or bank holding company. The listed company has also applied under § 225.23(a)(2) of Regulation Y (12 CFR 225.23(a)(2)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies, or to engage in such an activity. Unless otherwise noted, these activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 22, 1986.

A. Federal Reserve Bank of Atlanta
(Robert E. Heck, Vice President) 104
Marietta Street, NW., Atlanta, Georgia
30303:

1. *North Georgia Bancshares, Inc.*,
Canton, Georgia; to become a bank

holding company by acquiring 100 percent of the voting shares of North Georgia Bank, Canton, Georgia, which is currently operating as North Georgia Savings and Loan Association, Canton, Georgia.

Applicant has also applied to engage *de novo* through its subsidiary, N.G.B.S. Investments, Inc., Canton, Georgia, in operating a title insurance agency pursuant to section 4(c)(8)(C)(i) of the Bank Holding Company Act. These activities will be conducted in the area surrounding Canton and Woodstock, Georgia.

Board of Governors of the Federal Reserve System, July 25, 1986.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 86-17176 Filed 7-30-86; 8:45 am]

BILLING CODE 6210-01-M

**Security Holding, Inc., et al.;
Applications to Engage de Novo in
Permissible Nonbanking Activities**

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party

commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 19, 1986.

A. Federal Reserve Bank of Kansas City
(Thomas M. Hoenig, Vice President)
925 Grand Avenue, Kansas City,
Missouri 64198:

1. *Security Holding, Inc.*, Denver, Colorado; to engage *de novo* through its subsidiary, Securities Mortgage Funding Corporation, Denver, Colorado, in making and servicing loans and other extensions of credit as would be made by a mortgage company pursuant to § 225.25(b)(1) of the Board's Regulation Y. These activities will be conducted in Colorado.

B. Federal Reserve Bank of San Francisco
(Harry W. Green, Vice President)
101 Market Street, San Francisco, California 94105:

1. *Mission Valley Bancorp.*, Pleasanton, California; to engage directly in real estate advisory activities, including advising banks, other financial institutions and real estate development companies about loan procurement, joint venture participation, joint venture contracts, construction and loan disbursement supervision and similar activities pursuant to § 225.25(b)(4) of the Board's Regulation Y. Comments on this application must be received by August 20, 1986.

Board of Governors of the Federal Reserve System, July 25, 1986.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 86-17177 Filed 7-30-86; 8:45 am]

BILLING CODE 6210-01-M

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Alcohol, Drug Abuse, and Mental
Health Administration**

**Research Grants for Imaging
Technology in Alcohol Research**

AGENCY: National Institute on Alcohol Abuse and Alcoholism HHS.

ACTION: Issuance of a special program announcement for research grants on imaging technology in alcohol research.

SUMMARY: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) announces the availability of a special program announcement for Research Grants for Imaging Technology in Alcohol Research. These awards will

support research grants that utilize imaging biotechnology to study the etiology and pathology of alcoholism. Areas of research interest include biophysics and biochemistry at the molecular, cellular, tissue, organ, and whole body levels; histopathology; animal or human physiology and pathology; and other relevant clinical and biomedical disciplines. Supports may be requested for up to 5 years. It is estimated that up to \$1 million will be available in 1987 and future years, subject to final congressional action, to support research grants under this announcement.

Receipt Date for Applications: February 1, June 1, and October 1 of each year.

For a Copy of the Announcement Contact: The National Clearinghouse for Alcohol Information (NCALI), Box 2345, Rockville, Maryland 20852, Telephone (301) 468-2600.

Donald Ian Macdonald,

Administrator, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 86-17153 Filed 7-30-86; 8:45 am]

BILLING CODE 4160-20-M

Food and Drug Administration

[Docket No. 86F-0294]

EMS-CHEMIE AG; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that EMS-CHEMIE AG has filed a petition proposing that the food additive regulations be amended to provide for the safe use of Nylon 6/12 resin in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-56790.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5B3848) has been filed by EMS-CHEMIE AG, Domat, Switzerland, proposing that § 177.1500 *Nylon resins* (21 CFR 177.1500) be amended to provide for the safe use of Nylon 6/12 resin in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's

finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: July 24, 1986.

Sanford A. Miller,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 86-17182 Filed 7-30-86; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 86F-0279]

Milk Industry Foundation, the NutraSweet Co., and Beatrice Dairy Products, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the Milk Industry Foundation, the NutraSweet Co., and Beatrice Dairy Products, Inc., have filed a petition proposing that the food additive regulations be amended to provide for the safe use of aspartame as a sweetener in refrigerated flavored milk beverages.

FOR FURTHER INFORMATION CONTACT: Carl L. Giannetta, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-426-8950.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 6A3945) has been filed by the Milk Industry Foundation, 888 Sixteenth St. NW., Washington, DC 20006, Beatrice Dairy Products, Inc., 1526 South State St., Chicago, IL 60605, and The NutraSweet Co., 4711 Golf Rd., Skokie, IL 60076, proposing that § 172.804 *Aspartame* (21 CFR 172.804) be amended to provide for the safe use of aspartame as a sweetener in refrigerated flavored milk beverages.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c), as published in the **Federal Register** of April 26, 1985 (50 FR 16636).

Dated: July 24, 1986.

Sanford A. Miller,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 86-17184 Filed 7-30-86; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 86G-0289]

The National Fish Meal and Oil Association; Filing of Petition For Affirmation of Grasp Status

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a petition (GRASP 6G0316) has been filed on behalf of the National Fish Meal and Oil Association proposing to affirm that menhaden oil and partially hydrogenated menhaden oil are generally recognized as safe (GRAS) as direct human food ingredients.

DATE: Comments by September 29, 1986.

ADDRESS: Written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lawrence J. Lin, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. NW., Washington, DC 20204, 202-426-5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))) and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that a petition (GRASP 6G0316) has been filed on behalf of the National Fish Meal and Oil Association, 2000 M St. NW., Suite 580, Washington, DC 20036, proposing to affirm that menhaden oil and partially hydrogenated menhaden oil are GRAS for use as direct human food ingredients.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the format requirements outlined in § 170.35 is filed by the agency. There is no pre-filing review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this section is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's

finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Interested persons may, on or before September 29, 1986 review the petition and/or file comments (two copies, identified with the docket number found in brackets in the heading of this document) with the Dockets Management Branch (address above). Comments should include any available information that would be helpful in determining whether the substances are, or are not, GRAS. A copy of the petition and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: July 24, 1986.

Sanford A. Miller,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 86-17183 Filed 7-30-86; 8:45 am]

BILLING CODE 4160-01-M

National Institutes of Health

Meeting of the Fogarty International Center Advisory Board

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Fogarty International Center (FIC) Advisory Board, September 16, 17, 1986, in the Stone House (Building 16), at the National Institutes of Health.

The meeting will be open to the public on September 16 from 8:30 a.m. to 4:30 p.m. and on September 17 from 9:00 a.m. to 12 noon. On September 16, the agenda will include an Overview Report by Dr. Craig K. Wallace, Director of the FIC; reports from Advanced Studies, Research Awards, and Resources Working Groups, and from the Advisory Committee to the NIH Director; a presentation and discussion of the Administration's international science policy; a presentation on Biomedical Research and Research Training in Africa; and an overview of program evaluation at FIC, with specific focus on two recently completed evaluation projects. On September 17, the agenda includes a report from the World Health Assembly, and a review of needs for International Collaborative Research in Hepatitis. Attendance by the public will be limited to space available.

In accordance with the provisions of sections 552b(c)(4) and 552b(c)(6) of Title 5, U.S. Code, the meeting will be closed to the public on September 16, 1986, at 4:30 p.m. for review, discussion,

and evaluation of individual research fellowship applications. These applications contain information of a proprietary nature, including detailed research protocols, designs, and other technical information; and personal information about individuals associated with the applications.

Myra Halem, Committee Management Officer, Fogarty International Center, Building 38A, Room 609, and 301-496-1491, will provide a summary of the meeting and a roster of the committee members.

Dr. Coralie Farlee, Assistant Director for Planning and Evaluation, Fogarty International Center (Executive Secretary) Building 38A, Room 609, telephone 301-496-1491, will provide substantive program information.

Dated: July 22, 1986.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 86-17288 Filed 7-30-86; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Meeting of the Cancer Biology-Immunology Contract Review Committee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Cancer Biology-Immunology Contract Review Committee, National Cancer Institute, National Institutes of Health, August 15, 1986, Building 31, Conference Room 4, Bethesda, Maryland 20892.

This meeting will be open to the public on August 15, from 2:00 p.m. to 2:30 p.m., to review administrative details. Attendance by the public will be limited to space available.

In accordance with provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public on August 15, from approximately 2:30 p.m. until adjournment for the review, discussion and evaluation of contract proposals. These proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winifred Lumsden, the Committee Management Officer, National Cancer Institute, Building 31, Room 10A06, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members, upon request.

Dr. Wilna Woods, Executive Secretary, Cancer Biology-Immunology Contract Review Committee, National Cancer Institute, Westwood Building, Room 807, National Institutes of Health, Bethesda, Maryland 20892 (301/496-7030) will furnish substantive program information.

Dated: July 22, 1986.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 86-17289 Filed 7-30-86; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute, Meeting of Board of Scientific Counselors

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Heart, Lung, and Blood Institute Board of Scientific Counselors, November 13 and 14, 1986, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 7N214, Bethesda, Maryland 20892. This meeting will be open to the public from 9:00 a.m. to 4:00 p.m. November 13 and from 9:30 a.m. to 12 noon on November 14 for discussion of the general trends in research relating to cardiovascular, pulmonary and certain hematologic diseases. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in Section 552b(c)(6), Title 5, U.S. Code and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public from 12 noon to adjournment November 14 for the review, discussion, and evaluation of individual programs and projects conducted by the National Institutes of Health, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Terry Bellicha, Chief, Public Inquiry Reports Branch, National Heart, Lung, and Blood Institute, Building 31, Room 4A21, National Institutes of Health, Bethesda, Maryland 20892, phone (301) 496-4236, will provide a summary of the meeting and a roster of the Board members. Substantive program information may be obtained from Dr. Jack Orloff, Director, Division of Intramural Research, NHLBI, NIH, Building 10, Room 7N214, phone (301) 496-2116.